Advertisement

Organisation › Details
Nanobiotix S.A. (Euronext Paris: NANO, Nasdaq: NBTX)
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges. Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. *
![]() |
Start | 2003-01-01 established |
Group | Nanobiotix (Group) | |
![]() |
Industry | nanobiotechnology |
Industry 2 | oncology | |
![]() |
Person | Lévy, Laurent (NanoBiotix 201103 CEO) |
Person 2 | Mauberna, Philippe (Nanobiotix 201807 CFO) | |
![]() |
Region | Paris |
Country | France | |
Street | 60 Rue de Wattignies Bat B 3rd Floor | |
City | 75012 Paris | |
Tel | +33-1-4026-0470 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | C: 51 to 100 (2017-12-31) |
Currency | EUR | |
Annual sales | 3,721,525 (revenue, total (2017) 2017-12-31) | |
Profit | -26,143,249 (2017-12-31) | |
Cash | 47,200,000 (2017-12-31) | |
* Document for »About Section«: Nanobiotix S.A.. (4/4/19). "Press Release: Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval". Paris & Cambridge, MA. | ||
Record changed: 2024-02-12 |
Advertisement

More documents for Nanobiotix (Group)
- [1] Nanobiotix S.A.. (7/10/23). "Press Release: Nanobiotix Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3". Paris & Cambridge, MA....
- [2] Nanobiotix S.A.. (5/28/19). "Press Release: Nanobiotix Announces the Launch of Curadigm. A New Nanotechnology Platform for Healthcare". Paris & Cambridge, MA....
- [3] Nanobiotix S.A.. (4/4/19). "Press Release: Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval". Paris & Cambridge, MA....
- [4] Nanobiotix S.A.. (4/2/19). "Press Release: Combination of First-in-Class NBTXR3, Radiotherapy, and Anti-PD-1 Immunotherapy Demonstrate Efficacy in Treating Resistant Pre-clinical in Vivo Models of Lung Cancer". Paris & Cambridge, MA....
- [5] Nanobiotix S.A.. (1/16/19). "Press Release: Nanobiotix Plans to Conduct Registered Public Offering in the United States". Paris & Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top